Introduction
Cholesterol homeostasis in animal cells is achieved by regulated cleavage of sterol regulatory element binding proteins (SREBPs), which are membrane-bound transcription factors. Proteolytic release of the active domains of SREBPs from membranes requires a sterol-sensing protein called SREBP cleavage-activating protein (SCAP, MIM 601510), which forms a complex with SREBPs. SCAP, a central regulator of lipid synthesis and metabolism, is a membrane protein with multiple membrane-spanning segments, of which some show a highly significant resemblance to the membrane-spanning segments of 3-hydroxy-3-methylglutaryl coenzyme A reductase (MIM 142910) (Hua et al. 1996) . Thus, the role of SCAP is to escort the SREBPs from one cellular compartment to another in a sterol-regulated fashion (Osborne 2001) . In sterol-depleted cells, SCAP es-designed primers to amplify only the promoter and these 14 exons. Primers were designed to include at least 50 nucleotides within each intron at each intron-exon boundary, and more than 1 kb of the SCAP promoter. Primer sequences are shown in Table 2 . Amplification conditions for all reactions were 94°C for 5 min, followed by 30 cycles of 30 s each at 94°C, 60°C, and 72°C, and ending with a single 10-min extension step at 72°C. Purified amplification fragments were sequenced on a Prism 377 Automated DNA Sequencer (Applied Biosystems, Mississauga, Canada), and electropheretograms were interpreted using Sequence Navigator software (Applied Biosystems).
SNP genotyping
The SCAP promoter SNPs were genotyped from electropheretogram tracings of direct sequencing experiments in subjects of European and Chinese descent only. The SCAP 1644GϾA (VϾI407) SNP was detected using MslI digestion, as described . One additional synonymous SNP was found only in subjects of African descent, namely, exon 11 659AϾG. This was detected using primers shown in Table 2 and the amplification program described earlier, followed by digestion of the 582-bp product with endonuclease BsmFI. The 659G allele yielded one fragment with size 582 bp, and the 659A allele yielded two fragments with sizes 344 and 238 bp after BsmFI digestion. The polymorphic fragments were resolved on 2% agarose gels.
Statistical analysis SAS version 6.12 (SAS Institute, Cary, NC, USA) was used for statistical analyses. Allele frequencies were determined from gel electrophoresis images or from electropheretogram tracings of genomic DNA sequence. Chi-square analysis tested the deviation of genotype frequencies from Hardy-Weinberg predictions (nominal P Ͻ 0.05).
Construction of human SCAP/Luc reporters
Site-directed mutagenesis of site Ϫ11C/T in the SCAP promoter sequence was generated by the two-primer pair method. The mutagenesis primer pair was as follows: F-ACG CCG CGC TCC GCC CCT GCT GTC GCC CCC GT and R-ACG GGG GCG ACA GCA GGG GCG GAG CGC GGC GT, in which underlines represent mutated nucleotides. A genomic DNA fragment containing a 1.1-kb SCAP promoter sequence was obtained by amplification using primers F-GAA GAT CTC TTA CCT CTG ACA CAA GAC CTG G and R-GAA GAT CTA ACT CCC AGC TCC ACG CGG CTG, and the preceding amplification program. BglII endonuclease restriction sites were Values given as mean Ϯ SD F-GGG ATC ATA GGA TTC TTG GGA 405 R-AGA TAC TCG GCT CTT TCC CC introduced into both primers. The promoter fragment could thus be subcloned into the BglII site of the luciferase reporter, PGL3 basic vector (Promega, Madison, WI, USA). The fidelity of polymerase chain reaction replication and the introduction of the Ϫ11T mutation were subsequently confirmed by DNA sequence analysis.
Cell culture
The mouse cell line NIH-3T3 was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA, USA) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% (v/v) heated-inactivated fetal calf serum (Invitrogen).
Transient transfection assay
The NIH-3T3 cell cultures that were grown in six-well culture plates were transfected with plasmid by a standard calcium phosphate precipitation method (www.stanford.edu/group/nolan/index.html). Cells were seeded on six-well plates to achieve 60%-70% confluence and transfected with SCAP promoter reporter constructs containing either mutant or the control promoter sequence in either correct or reverse orientation. For each transfection, we prepared the DNA (8 µg/60 mm) in a specified amount of 2 ϫ HEPES buffered saline and 2 M CaCl 2 solution, and added the solution dropwise to the cells. For each transfection with the SCAP-containing vector, 2 µg pSVbeta-galactosidase vector (ProFection Mammalian Transfection System, Promega) was cotransfected according to the manufacturer's instructions. The transfection solution was removed after 20 h incubation at 37°C and replaced by fresh medium for a further culture. Cells were harvested 48 h posttransfection, and the reporter activity was determined with the luciferase assay. The beta-galactosidase enzyme assay system was used for normalization (Promega). For beta-galactosidase assays, 150 µl cell lysate was mixed with 150 µl 2ϫ assay buffer and incubated at 37°C for 3 h. The reaction was stopped by the addition of 500 µl of 1M sodium carbonate and absorbance at 420 nm was read spectrophotometrically. A blank was prepared using the lysate made from cells that were not transfected with the beta-galactosidase gene.
Luciferase reporter assay
Luciferase activity was assayed according to the manufacturer's instructions (Promega) and luminescence was determined using a Lumat LB9507 luminometer (Berthold Systems, Pittsburgh, PA, USA). Luciferase activities were normalized for transfection efficiencies using reporter luciferase units per unit of activity of beta-galactosidase (RLU/B-Gal). Each data point was the average of triplicate assays from two experiments.
Results

Identification of SCAP polymorphisms
Genomic DNA sequencing experiments in 64 CH and 130 normal control subjects uncovered seven SCAP polymorphisms (Table 3 ). All observed genotype frequencies did not deviate from Hardy-Weinberg expectations. There were four common promoter SNPs, namely, Ϫ933GϾA, Ϫ440TϾA, Ϫ439CϾA, and Ϫ177GϾC. These were frequent in both diseased subjects and in controls from three ethnic groups (Table 3 ). The Ϫ933G, Ϫ440A, and Ϫ439A allele were in almost perfect linkage disequilibrium and formed a common haplotype in all subgroups examined (coefficient of disequilibrium Ͼ0.95 for each ethnic group). A silent SNP in exon 11, namely, 659AϾG, was observed only in subjects of African descent (Table 3 ). The previously reported non-synonymous exon 15 1644GϾA SNP (Iwaki et al. 1999 ) was found at varying frequency in all ethnic groups. Finally, a rare promoter SNP Ϫ11CϾT was found only in two subjects with CH. The affected heterozygotes for the SCAP Ϫ11CϾT SNP were (1) a 54-year-old man with untreated plasma concentrations of total, LDL, and high-density lipoprotein (HDL) cholesterol of 5.17, 3.70, and 0.79 mmol/l, respectively, and a plasma triglyceride concentration of 2.70 mmol/l; and (2) a 57-year-old woman with untreated plasma concentrations of total, Chi-square analysis showed no significant difference in allele frequency between subjects with CH and normal Caucasian controls (P ϭ 0.56).
SCAP promoter activity assay
Sequencing showed that the background promoter sequence for each reporter construct contained Ϫ933G, Ϫ440T, Ϫ439C, and Ϫ177G. The difference was the presence of Ϫ11C for the wild-type construct and Ϫ11T for the mutant construct. The negative control construct contained the wild-type sequence, but in the reverse orientation. Mean normalized luciferase activities from triplicate experiments performed on two separate days are shown in Fig. 1 . The normalized luciferase activity (RLU) was decreased by more than 20-fold for the mutant compared with the wild type (P Ͻ 0.001).
Discussion
We report the identification of a loss-of-function Ϫ11CϾT promoter mutation for SCAP. This mutation was found in two unrelated subjects who were ascertained based on a biochemical diagnosis of CH, but was absent from normolipidemic subjects across three ethnic groups. The Ϫ11T allele was associated with a marked reduction in promoter activity in a luciferase-based expression system. It is not clear whether heterozygosity for a dysfunctional promoter mutation in SCAP, even one associated with as severe loss of function in an in vitro expression assay as Ϫ11CϾT, would be associated with any consequence at the clinical level. Liver-specific targeted deletion of SCAP in mice resulted in low serum concentrations of cholesterol and triglycerides (Matsuda et al. 2001) , which was opposite to the CH phenotype observed in heterozygotes for Ϫ11CϾT. Because SREBPs are key activators of lipogenesis, the liver-specific-SCAP-less mice cannot appropriately escort SREBP promoters to cellular compartments containing the proteases that produce active SREBP cleavage products, which results in diminished lipogenesis under both fasting and fed conditions (Matsuda et al. 2001; Osborne 2001 ). However, human heterozygotes for SCAP Ϫ11CϾT differ from liver-specific-SCAP-less mice, because there is only a partial reduction in the capacity to generate normal SCAP, and this occurs in both hepatic and extrahepatic tissues. This distinction, taken together with interspecies differences and the overall complexity of cholesterol metabolism and fatty acid biosynthesis, could explain the apparently counterintuitive human phenotype.
Another potential confounding issue is that of tissue specificity. Our assay of promoter function was determined in a murine adipocyte cell line. Although NIH-3T3 cells were previously shown to be useful for analyzing SREBP activation (Inoue et al. 2001) , it remains possible that there are differences between cell lines. In addition, there might also have been unmeasured genetic and/or environmental factors that could have affected expression of the phenotype in the human SCAP Ϫ11CϾT heterozygotes in whom the mutation was first identified. Alternatively, this rare loss-of-function SCAP promoter mutation may have played no role in the abnormal lipoprotein phenotype in the two affected subjects, and was simply an incidental finding. Studies of much larger experimental samples will be required to establish whether there is a statistical association between the rare loss-of-function mutation in SCAP and a dyslipidemic phenotype.
We also found additional promoter SNPs in SCAP, namely, Ϫ933GϾA, Ϫ440TϾA, Ϫ439CϾA, and Ϫ177GϾC, which were common in control subjects from three ethnic groups. We also identified a silent SNP in exon 11, namely, 659AϾG, which was observed only in subjects of African descent. In addition, we found that the frequency of a previously reported common nonsynonymous SCAP SNP, namely, 1644GϾA (Iwaki et al. 1999) , varied in frequency across ethnic groups. The identification of additional SCAP SNPs provides tools for studies of association with metabolic phenotypes. Fig. 1 . Results of in vitro expression analysis of luciferase reporter constructs containing wild-type SCAP promoter (WT), a negative control construct made by cloning of WT promoter in the reverse orientation (negative), and a construct containing the Ϫ11CϾT polymorphism (SNP). Normalized reporter luciferase units (RLU) per unit of betagalactosidase activity (B-Gal) are shown for two sets of triplicate experiments. Means Ϯ standard deviations are shown. The asterisk refers to a significant difference between mean WT and SNP normalized expression (P Ͻ 0.001)
